Results 71 to 80 of about 10,075 (184)
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
, 2021 Vaccines against SARS-CoV-2 are urgently required, but early development of vaccines against SARS-CoV-1 resulted in enhanced disease after vaccination. Careful assessment of this phenomena is warranted for vaccine development against SARS CoV-2.
Sharpe, Hannah +87 more
core +1 more source
Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19 [PDF]
The Korean Journal of Internal Medicine, 2022 Background/Aims Data comparing the antibody responses of different coronavirus disease 2019 (COVID-19) vaccine platforms according to dose with natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection-induced antibody responses are ...
Hye Hee Cha +6 more
doaj +1 more source
Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
Journal of Korean Medical Science, 2021 Since February 26, 2021, when vaccination against coronavirus disease 2019 (COVID-19) began in South Korea, patients who visited the Korea University Guro Hospital with suspected adverse events after COVID-19 vaccination were monitored actively with interest.
Hakjun Hyun +6 more
openaire +2 more sources
Vaccines, 2022 Cerebral venous thrombosis (CVT), a rare thrombotic event that can cause serious neurologic deficits, has been reported after some ChAdOx1 nCoV-19 vaccinations against coronavirus disease 2019 (COVID-19).
Jin Park +3 more
doaj +1 more source
, 2022 The emergence of SARS-CoV-2 variants raises concerns of reduced COVID-19 vaccine efficacy. We investigated the humoral immunity in uninfected and previously infected ChAdOx1 nCoV-19, BNT162b2 and CoronaVac vaccinees, who have received complete regimes of
Chua, Jia Xin +7 more
core +1 more source
Vaccines, 2023 Introduction: In Italy, on December 2020, workers in the education sector were identified as a priority population to be vaccinated against COVID-19.
Paola Mason +18 more
doaj +1 more source
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil [PDF]
, 2021 Several COVID-19 vaccines have shown good efficacy in clinical trials, but there remains uncertainty about the efficacy of vaccines against different variants. Here, we investigate the efficacy of ChAdOx1 nCoV-19 (AZD1222) against symptomatic COVID-19 in
Sprinz, Eduardo +27 more
core +2 more sources
Thrombosis with thrombocytopenia cases reported following ChAdOx1 nCov-19 vaccination (AstraZeneca).
, 2023 Thrombosis with thrombocytopenia cases reported following ChAdOx1 nCov-19 vaccination (AstraZeneca).
Petteri Hovi (331278) +8 more
core +1 more source
Bleeding, Thrombosis and Vascular Biology, 2022 Vaccination with ChAdOx1 nCoV-19 can result in vaccine-induced immune thrombotic thrombocytopenia (VITT). This phenomenon mimics heparin-induced thrombocytopenia, yet it does not require heparin as a trigger.
Rita Carlotta Santoro +8 more
doaj +1 more source
Journal of Acute Disease, 2022 Objective: To determine the real-world effectiveness of the ChAdOx1 nCoV-19 coronavirus vaccine in preventing severe disease and mortality due to COVID-19.
Priyanka Rajmohan +5 more
doaj +1 more source